Flash talks on barzolvolimab clinical program in CSU and Cold Urticaria ---- Late-breaking poster presentation on CDX-622 --HAMPTON, N.J., ...

Aplagon, a clinical-stage biotechnology company developing APAC, a first-in-class antiplatelet and anticoagulant therapeutic platform for thrombo-inflammatory diseases, today announced the appointment ...

Elon Musk is widely regarded as one of the most influential entrepreneurs of the modern era. On June 12, the 54-year-old officially became the world's first trillionaire, driven by the historic ...

While Evommune is terminating development of the oral drug in CSU, trials in AD and migraine prophylaxis will continue.

Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of ...

Is there really a mushroom that can help allergy sufferers? Here's what the research says so far.

Evommune’s recent miss with EVO756's CSU indications is a major setback. Read why I think the selloff in EVMN stock is ...

Rosie the dog had her tumours treated by an mRNA vaccine developed with the help of artificial intelligence. Her owner had decided to explore treatment options using AI chatbots.

No, it's not your imagination, and we have the scientific proof ...

Reishi mushrooms have long been discussed for their health benefits, and many are wondering if the chatter about allergies is ...

TheFly reported on June 10 that UBS increased its price target on CLDX to $45 from $38 while maintaining a Buy rating on the ...

TheFly reported on June 10 that UBS increased its price target on CLDX to $45 from $38 while maintaining a Buy rating on the ...